Superficial urinary bladder carcinoma

Active Ingredient: Mitomycin

Indication for Mitomycin

Population group: only elderly (65 years old or older)

Intravesical administration for relapse prevention in superficial urinary bladder carcinoma after transurethral resection.

For this indication, competent medicine agencies globally authorize below treatments:

20-40 mg once every week

Route of admnistration

Intravesical

Defined daily dose

20 - 40 mg

Dosage regimen

From 20 To 40 mg once every 7 day(s)

Detailed description

In intravesical therapy, 20-40 mg of mitomycin in 20-40 ml of phosphate buffer pH 7.4 or sodium chloride (0.9%) solution, is instilled weekly into the bladder. The treatment period is 8 to 12 weeks. In the case of intravesical administration the urine pH should be higher than pH 6.

4-10 mg once every other day

Route of admnistration

Intravesical

Defined daily dose

4 - 10 mg

Dosage regimen

From 4 To 10 mg once every 2 day(s)

Detailed description

Alternative dose recommendation in the prevention of recurrent superficial bladder tumours is 4-10 mg (0.06-0.15 mg/kg of body weight) instilled into the bladder though a urethral catheter 1 or 3 times per week.

Dosage considerations

The solution should be retained in the bladder for 1-2 hours.

0.06-0.15 mg/kg once every other day

Route of admnistration

Intravesical

Defined daily dose

0.06 - 0.15 mg per kg of body weight

Dosage regimen

From 0.06 To 0.15 mg per kg of body weight once every 2 day(s)

Detailed description

Alternative dose recommendation in the prevention of recurrent superficial bladder tumours is 4-10 mg (0.06-0.15 mg/kg of body weight) instilled into the bladder though a urethral catheter 1 or 3 times per week.

Dosage considerations

The solution should be retained in the bladder for 1-2 hours.

Active ingredient

Mitomycin

Mitomycin is an antibiotic isolated from Streptomyces caespitosus with anti-neoplastic effect. The mechanism of action is based predominantly on the alkylation of DNA (RNA to a lesser extent) with the corresponding inhibition of DNA synthesis. The degree of DNA damage correlates with the clinical effect and is lower in resistant cells than in sensitive ones.

Read more about Mitomycin

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.